纤维肌痛在普通人群和高危亚群中的患病率:系统综述与荟萃分析
该系统综述与荟萃分析纳入882项研究,覆盖38个国家。普通人群纤维肌痛汇总患病率为1.40%(95%CI 0.49-2.47),异质性高(I2=100%),证据确定性极低。高危亚群患病率显著更高,如慢性荨麻疹37.1%。发表年份和人类发展指数是患病率的显著调节因素。
要点
- 普通人群纤维肌痛患病率约1%至2%,全球汇总值为1.40%。
- 自身免疫和炎症性疾病等高危亚群患病率显著升高,可达20%至37%。
- 发表年份和人类发展指数与患病率变异显著相关,提示诊断不一致和医疗差距。
核心结论
- 纤维肌痛影响全球1%至2%的人口,高危亚群患病率显著更高。
- 时间和 socioeconomic 趋势强调诊断不一致和全球医疗差距。
研究设计与样本
- 系统综述与荟萃分析,检索21645条记录,全文审查1728篇,最终纳入882项研究。
- 普通人群分析纳入188项研究,覆盖38个国家、30070032人。
- 高危亚群分析纳入768项研究,共9771123名参与者。
- 采用Freeman-Tukey转化的逆方差异质性模型计算汇总患病率及95%CI。
主要发现
- 普通人群纤维肌痛汇总患病率为1.40%(95%CI 0.49-2.47),异质性I2=100%,证据确定性极低。
- 高危亚群中患病率显著升高:慢性荨麻疹37.1%、间质性膀胱炎30.8%、系统性硬化症20.6%、乳糜泻20.5%、炎症性肠病19.9%。
- 慢性疼痛、风湿病和感染后队列中患病率也升高。
- 荟萃回归显示发表年份(β=0.008,P<.001)和人类发展指数(β=0.725,P=.002)是患病率的显著调节因素。
关键数值与推荐
- 普通人群汇总患病率1.40%(95%CI 0.49-2.47),基于188项研究、30070032人。
- 高危亚群患病率:慢性荨麻疹37.1%、间质性膀胱炎30.8%、系统性硬化症20.6%、乳糜泻20.5%、炎症性肠病19.9%。
- 发表年份β=0.008,P<.001;人类发展指数β=0.725,P=.002。
临床怎么用
- 麻醉科医生应识别纤维肌痛高危患者,尤其是合并自身免疫或炎症性疾病者。
- 对高危亚群患者,术前评估需关注纤维肌痛可能,以优化围术期疼痛管理。
局限性
- 异质性极高(I2=100%),证据确定性极低。
- 诊断标准和研究方法差异可能导致患病率估计变异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Estimates of fibromyalgia prevalence vary widely worldwide due to differences in diagnostic criteria, study methodology, and population characteristics. Accurate estimates are essential to inform population-level surveillance, guide resource allocation, and highlight disparities in disease recognition and access to care. The objective of this systematic review and meta-analysis was to determine the global prevalence of fibromyalgia in the general population, and secondarily to identify factors moderating prevalence variation and to assess prevalence in defined at-risk subpopulations. Pooled prevalence estimates with 95% confidence intervals (CIs) were calculated using the inverse variance heterogeneity model with Freeman-Tukey transformation. Subgroup analyses were performed by sex, diagnostic criteria, country, and other study characteristics, and meta-regression assessed moderators including publication year and Human Development Index (HDI). Of 21,645 records identified, 1,728 underwent full-text review and 882 studies were included in the final analysis. Across 38 countries and 30,070,032 individuals (188 studies), the pooled fibromyalgia prevalence in the general population was 1.40% (95% CI, 0.49-2.47), with substantial heterogeneity (I2 = 100%) and very low certainty of evidence. Among at-risk subpopulations (9,771,123 participants; 768 studies), prevalence was markedly higher in autoimmune and inflammatory conditions, such as chronic urticaria (37.1%), interstitial cystitis (30.8%), systemic sclerosis (20.6%), celiac disease (20.5%), and inflammatory bowel disease (19.9%), and elevated in chronic pain, rheumatologic, and post-infection cohorts. Meta-regression identified publication year (β = 0.008, P < .001) and HDI (β = 0.725, P = .002) as significant moderators of prevalence. In conclusion, fibromyalgia affects 1% to 2% of the global population, with substantially higher rates in at-risk subpopulations. Temporal and socioeconomic trends emphasize diagnostic inconsistency and global disparities in care.
引用
- D'Souza RS, Klasova J, Morsi M, et al. The Prevalence of Fibromyalgia in the General Population and At-Risk Subpopulations: A Systematic Review and Meta-Analysis. Anesth Analg. 2026. PMID: 42201834. doi:10.1213/ANE.0000000000008098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。